Galera Therapeutics, Inc.

GRTX · OTC · SIC 2834: Pharmaceutical Preparations
104
SEC Filings

Business Summary

PART I Item 1. B usiness. Overview We are a biopharmaceutical company that historically was focused on developing a portfolio of small molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, primarily by reducing one of the most common side effects of radiotherapy, severe oral mucositis (SOM). In October 2025 we sold our assets related to avasopasem and rucosopasem and all other dismutase mimetics assets to Biossil, Inc. (Biossil), a privately-held company based in Toront...

Next Earnings

Q2 FY2026 — expected 2026-09-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionGRTXdiscussed_in_filing Cybersecurity
topic_mentionGRTXdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001563577-26-000005EDGAR67K words
2025-03-312024-12-310000950170-25-047798EDGAR—
2024-03-282023-12-310000950170-24-037614EDGAR—
2023-03-082022-12-310000950170-23-006588EDGAR—
2022-03-102021-12-310000950170-22-003292EDGAR—
2021-03-112020-12-310001564590-21-012244EDGAR—
2020-03-102019-12-310001564590-20-009542EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001193125-25-278816EDGAR19K words
2025-08-132025-06-300000950170-25-107616EDGAR—
2025-05-152025-03-310000950170-25-071956EDGAR—
2024-12-132024-09-300001193125-24-277849EDGAR—
2024-08-142024-06-300000950170-24-096654EDGAR—
2024-05-132024-03-310000950170-24-058197EDGAR—
2023-11-142023-09-300000950170-23-063361EDGAR—
2023-08-142023-06-300000950170-23-042058EDGAR—
2023-05-112023-03-310000950170-23-020842EDGAR—
2022-11-092022-09-300000950170-22-023516EDGAR—
2022-08-092022-06-300000950170-22-015753EDGAR—
2022-05-162022-03-310000950170-22-009950EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-030001193125-26-141187EDGAR1K words
2026-02-180001193125-26-055919EDGAR—
2026-02-120001193125-26-048696EDGAR—
2025-10-270001193125-25-250698EDGAR—
2025-10-210001193125-25-245093EDGAR—
2025-09-030001193125-25-194948EDGAR—
2025-04-020001193125-25-071428EDGAR—
2025-02-250001193125-25-035114EDGAR—
2024-12-310001193125-24-287073EDGAR—
2024-12-200001193125-24-283187EDGAR—

104 total filings indexed. 75 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001563577
TickerGRTX
ExchangeOTC
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 0d9b414e6d9ac8875968de01aeb186e2e95ce5d38d7cac7a3c9d9f88f5718dc8
parent: 87fa9cab7ceb211ad6637e7abb4fcc65afbac384738f68f694c34aaa2925fff7
content hash: 175d76e00d563fa6451ef1a1c240bf982e00f8ce8d90fbc4626641f6ceab290a
signed: 2026-04-13T04:45:23.065Z
sources: 19 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf